HTGCMEDIUM SIGNALFINANCIAL10-K

HTGC significantly expanded its debt investment portfolio while experiencing a massive 261% deterioration in operating cash flow despite strong net income growth.

The dramatic disconnect between growing net income (+29%) and severely declining operating cash flow (-261%) suggests potential timing differences or quality of earnings concerns that warrant close monitoring. The substantial portfolio expansion into application software debt investments indicates an aggressive growth strategy that has increased leverage and risk exposure.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

HTGC demonstrated strong asset growth (+20%) and improved profitability with net income rising 29% to $340M, though this came with higher financing costs as interest expense increased 24%. However, the most concerning development is the severe deterioration in operating cash flow from -$118M to -$426M, a 261% decline that starkly contrasts with reported earnings growth. The company funded expansion through increased debt (+29%) while maintaining adequate liquidity with cash rising 33% to $57M, but the cash flow dynamics suggest potential quality of earnings issues or significant working capital pressures.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-260.6%
-$118.1M-$425.8M

Operating cash flow fell 260.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Share Buybacks
Cash Flow
+89.2%
$3.4M$6.5M

Share repurchases increased 89.2% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
+33.3%
$42.7M$56.9M

Cash position surged 33.3% — strong cash generation or capital raise providing significant financial cushion.

Total Debt
Balance Sheet
+29.3%
$1.8B$2.3B

Debt rose 29.3% — additional borrowing for investment or operations; monitor coverage ratios.

Net Income
P&L
+29.2%
$263.0M$339.7M

Net income grew 29.2% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
+28.6%
$1.8B$2.4B

Liabilities increased 28.6% — monitor debt-to-equity ratio and interest coverage.

Interest Expense
P&L
+24.2%
$62.3M$77.5M

Interest costs rose 24.2% — monitor debt levels and coverage ratio in rising rate environment.

Total Assets
Balance Sheet
+19.6%
$3.8B$4.6B

Asset base grew 19.6% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+11.4%
$2.0B$2.2B

Equity base grew 11.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
and Senior Secured and Maturity Date February 2029 and Prime + 3.50%, Floor rate 10.00%, 3.50% Exit Fee 2025-12-31 0001280784 Debt Investments Application Software and Ceros, Inc.
and Senior Secured and Maturity Date June 2027 and 3-month SOFR + 8.99%, Floor rate 9.89% 2025-12-31 0001280784 Debt Investments Application Software and Chainalysis, Inc.
and Senior Secured and Maturity Date June 2029 and Prime + 2.95%, Floor rate 10.45% 2025-12-31 0001280784 Debt Investments Application Software and Dashlane, Inc.
and Senior Secured and Maturity Date December 2027 and Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee 2025-12-31 0001280784 Debt Investments Application Software and Dispatch Technologies, Inc.
and Senior Secured and Maturity Date April 2028 and 3-month SOFR + 7.86%, Floor rate 8.61% 2025-12-31 0001280784 Debt Investments Application Software and Distributed Creation Inc.
+7 more — sign up free →
REMOVED
2024-12-31 0001280784 Equity Investments Software and SirionLabs Pte.
Warrant, Acquisition Date 8/24/2023, Series Common Stock 2024-01-01 2024-12-31 0001280784 Warrant Investments and Software and Suzy, Inc.
Gibraltar Business Capital, LLC), Equity, Acquisition Date 3/1/2018, Series Member Units 2023-01-01 2023-12-31 0001280784 Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a.
AcelRx Pharmaceuticals, Inc.), Equity, Acquisition Date 12/10/2018, Series Common Stock 2023-01-01 2023-12-31 0001280784 Equity Investments Drug Delivery and Talphera, Inc.
Applied Molecular Transport)., Equity, Acquisition Date 4/06/2021, Series Common Stock 2023-01-01 2023-12-31 0001280784 Equity Investments Drug Discovery Development and Cyclo Therapeutics, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →